These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 27230919)

  • 1. Twelve-month outcomes of treatment using ranibizumab or aflibercept for neovascular age-related macular degeneration: a comparative study.
    Kim JH; Lee DW; Chang YS; Kim JW; Kim CG
    Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2101-2109. PubMed ID: 27230919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neovascular age-related macular degeneration treated with ranibizumab or aflibercept in the same large clinical setting: visual outcome and number of injections.
    Rasmussen A; Sander B; Larsen M; Brandi S; Fuchs J; Hansen LH; Lund-Andersen H
    Acta Ophthalmol; 2017 Mar; 95(2):128-132. PubMed ID: 27535819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization.
    Van Lancker L; Petrarca R; Moutsouris K; Masaoutis P; Kampougeris G
    Eur J Ophthalmol; 2017 May; 27(3):342-345. PubMed ID: 27739561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term choroidal thickness changes in patients treated with either ranibizumab or aflibercept: a comparative study.
    Kim JH; Lee TG; Chang YS; Kim CG; Cho SW
    Br J Ophthalmol; 2016 Dec; 100(12):1634-1639. PubMed ID: 26951770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Change in choroidal thickness after intravitreal injection for treatment of neovascular age-related macular degeneration: Ranibizumab versus aflibercept.
    Kaya F
    J Fr Ophtalmol; 2017 Dec; 40(10):832-838. PubMed ID: 29113742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. INTRAVITREAL AFLIBERCEPT AND RANIBIZUMAB INJECTIONS FOR TYPE 3 NEOVASCULARIZATION.
    Cho HJ; Hwang HJ; Kim HS; Han JI; Lee DW; Kim JW
    Retina; 2018 Nov; 38(11):2150-2158. PubMed ID: 28984737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of intravitreal aflibercept and ranibizumab injections on subfoveal and peripapillary choroidal thickness in eyes with neovascular age-related macular degeneration.
    Yun C; Oh J; Ahn J; Hwang SY; Lee B; Kim SW; Huh K
    Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1693-702. PubMed ID: 26781585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
    Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Ng P; Pecheur FL; McAllister IL
    JAMA Ophthalmol; 2019 Apr; 137(4):372-379. PubMed ID: 30676617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study).
    Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Pecheur FL; Munk MR; McAllister IL
    Ophthalmology; 2020 Feb; 127(2):198-210. PubMed ID: 31619357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
    Park DH; Sun HJ; Lee SJ
    Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD.
    Batioglu F; Demirel S; Özmert E; Abdullayev A; Bilici S
    BMC Ophthalmol; 2015 Apr; 15():40. PubMed ID: 25885684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
    Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
    Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Choroidal Thickness Changes After Intravitreal Antivascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration: Ranibizumab Versus Aflibercept.
    Gharbiya M; Cruciani F; Mariotti C; Grandinetti F; Marenco M; Cacace V
    J Ocul Pharmacol Ther; 2015; 31(6):357-62. PubMed ID: 26133059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
    Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
    Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and Type 1 neovascular age-related macular degeneration.
    Matsumoto H; Hiroe T; Morimoto M; Mimura K; Ito A; Akiyama H
    Jpn J Ophthalmol; 2018 Mar; 62(2):144-150. PubMed ID: 29411171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration.
    Abdin AD; Suffo S; Asi F; Langenbucher A; Seitz B
    Graefes Arch Clin Exp Ophthalmol; 2019 Aug; 257(8):1671-1677. PubMed ID: 31144055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times.
    Fauser S; Muether PS
    Br J Ophthalmol; 2016 Nov; 100(11):1494-1498. PubMed ID: 26888975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multimodal imaging based biomarkers predictive of early and late response to anti-VEGFs during the first year of treatment for neovascular age-related macular degeneration.
    Tarakcioglu HN; Ozkaya A; Kemer B; Taskapili M
    J Fr Ophtalmol; 2019 Jan; 42(1):22-31. PubMed ID: 30578008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retinal and Choroidal Changes after Anti Vascular Endothelial Growth Factor Therapy for Neovascular Age-related Macular Degeneration.
    Kim SW; Woo JE; Yoon YS; Lee S; Woo JM; Min JK
    Curr Pharm Des; 2019; 25(2):184-189. PubMed ID: 30892159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set.
    Lotery A; Griner R; Ferreira A; Milnes F; Dugel P
    Eye (Lond); 2017 Dec; 31(12):1697-1706. PubMed ID: 28731052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.